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Abstract
Parasitic flatworms are responsible for serious infectious diseases that affect humans as well as livestock animals in vast
regions of the world. Yet, the drug armamentarium available for treatment of these infections is limited: praziquantel is the
single drug currently available for 200 million people infected with Schistosoma spp. and there is justified concern about
emergence of drug resistance. Thioredoxin glutathione reductase (TGR) is an essential core enzyme for redox homeostasis in
flatworm parasites. In this work, we searched for flatworm TGR inhibitors testing compounds belonging to various families
known to inhibit thioredoxin reductase or TGR and also additional electrophilic compounds. Several furoxans and one
thiadiazole potently inhibited TGRs from both classes of parasitic flatworms: cestoda (tapeworms) and trematoda (flukes),
while several benzofuroxans and a quinoxaline moderately inhibited TGRs. Remarkably, five active compounds from diverse
families possessed a phenylsulfonyl group, strongly suggesting that this moiety is a new pharmacophore. The most active
inhibitors were further characterized and displayed slow and nearly irreversible binding to TGR. These compounds
efficiently killed Echinococcus granulosus larval worms and Fasciola hepatica newly excysted juveniles in vitro at a 20 mM
concentration. Our results support the concept that the redox metabolism of flatworm parasites is precarious and
particularly susceptible to destabilization, show that furoxans can be used to target both flukes and tapeworms, and
identified phenylsulfonyl as a new drug-hit moiety for both classes of flatworm parasites.
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Introduction
Flatworm infections are a major cause of human disability and
mortality in many developing countries, and remains as one of the
most important challenges for medicine in the 21
st century [1,2].
In addition, many flatworms parasitize livestock and cause
economically important diseases. Flatworm parasites include two
major lineages: flukes (class Trematoda) and tapeworms (class
Cestoda). Liver fluke disease is caused by endoparasitic trematodes
of the genus Fasciola. Fasciola hepatica, the common liver fluke,
widely distributed in temperate climates, causes massive economic
losses to livestock production due to reduction in meat, wool and
milk output in infected animals. Its significance as an emerging
food-borne zoonosis in parts of Latin America and Africa, with
millions at risk of infection, has been recognized by the WHO [3].
Fasciolosis control is dependent on repeated treatment with
anthelmintic drugs. However, resistant strains against triclabenda-
zole, the drug of choice, have appeared in Europe and Australia
[4]. Cystic echinococcosis or cystic hydatid disease caused by the
larval stage of the dog tapeworm Echinococcus granulosus, the most
widespread zoonosis caused by a cestode, remains a serious threat
to human health. Control programs of cystic echinococcosis are
based on repeated anthelmintic treatment of dogs with prazi-
quantel [5]. For the larval stage, chemotherapy with benzimid-
azoles is combined with surgical removal of the cyst. In the case of
alveolar echinococcosis or alveolar hydatid disease, caused by
Echinococcus multilocularis infection, continuous chemoprophylaxis
with benzimidazoles leads to a good quality of life for most patients
with the chronic disease [6]. Despite the medical relevance of
flatworm infections, the tools available to their control are very
limited: there is no single vaccine available for a human flatworm
infection, and the pharmacological arsenal for many of them
consists of just a single drug, for which there is concern of drug
resistance emergence and/or spreading [7,8]. Indeed, praziquan-
tel is the single effective drug for schistosomiasis treatment, the
main chronic disease caused by flatworms, infecting 200 million
people in tropical regions. Despite the urgent need for novel
effective anti-flatworms drugs, discovery and development re-
search has been sparse over the last decade. A rational target-
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to accelerate the process.
An unusual metabolic aspect of flatworm parasites is their
unique array of thiol-based redox pathways. In contrast to most
organisms, including their mammalian hosts, flatworm parasites
possess the selenoenzyme thioredoxin glutathione reductase
(TGR) as a single core enzyme for thioredoxin- and glutathione-
dependent pathways [9,10,11]. Thus, antioxidant defenses, redox
homeostasis and DNA synthesis in flatworm parasites depends on
a single essential enzyme that has been validated as a drug target
for Schistosoma mansoni infection. This work led to high throughput
screening of TGR inhibitors and to the identification of
oxadiazoles, among others, as new drug leads for the control of
schistosomiasis [12,13,14]. It has also recently been demonstrated
that auranofin, a specific gold inhibitor of selenocysteine (Sec)
containing TRs and TGRs, kills in vitro Echinococcus granulosus and
Taenia cracisseps larval worms, indicating that TGR is an essential
enzyme in cestodes [15,16]. Tapeworm TGR also fulfills other
requirements as a drug target: it is constitutively expressed, there is
a low cost and simple biochemical assay to test its activities, and
importantly it is a ‘‘druggable enzyme’’. The Sec residue in TGRs
contains a nucleophilic, highly reactive side chain that is a highly
susceptible target site for electrophiles. Based on these premises,
we selected 65 compounds as candidate TGR inhibitors from our
chemical library of compounds belonging to different families of
electrophililic systems as well as known TR and TGR inhibitors.
We identified new oxadiazole N-oxides (also known as furoxans), a
quinoxaline, and a thiadiazole as inhibitors for flukes and
tapeworms. Furthermore, several active compounds belonging to
the different families contain the phenylsulfonyl moiety suggesting
that this group is a potential new pharmacophore to target
flatworm TGRs. The identified inhibitors of TGR were able to kill
in vitro cestode larval worms of E. granulosus and the invasive
juvenile stage of F. hepatica in vitro.
Materials and Methods
Selection of compounds
Compounds were selected from previously synthesized products
available from our chemical library (see references in Table S1),
taking into account previously identified S. mansoni TGR inhibitors
[13,14], Plasmodium falciparum TR inhibitors [17], and additional
compounds with electrophilic groups. In total, 65 compounds
belonging to the following structural families were selected:
oxadiazole N-oxide or furoxan (21), benzofuroxan (28), thiadiazole
(11), quinoxaline (3), nitrooxy-derivative (1) and oxathiazole (1).
Figure 1 shows the general structures of the compound families
assayed as inhibitors of TGR; Table S1 shows the structures of
every compound assayed.
Cloning, expression and purification of E. granulosus and
F. hepatica wild-type TGRs
The construct for recombinant expression of E. granulosus TGR
was previously generated [15].The construct for F. hepatica TGR
was generated using the same methodology [18]. Both TGR
constructs contained the Sec insertion sequence (SECIS) element
of E. coli formate dehydrogenase H at a 10 nucleotide distance
from the penultimate UGASec codon, to allow stop codon recoding
to Sec, as previously described [15,18]. For recombinant protein
expression, TGR constructs were used to transform E. coli
BL21(DE3) cells previously transformed with pSUABC, a plasmid
that encodes selA, selB and selC, supporting high level expression of
the genes involved in Sec incorporation [19]. Expression of TGRs
was carried out following the protocol described in [20], which has
been optimized for expression of selenoproteins. Essentially,
induction of recombinant protein was carried out with 100 mM
IPTG in late exponential phase (OD600=2.4), during 24 h at
24uC. Recombinant clones were grown in modified LB media
according to [21], supplemented with 0.1 g/L cysteine and
0.37 g/L methionine [22], in the presence of kanamycin (50 mg/
mL), and chloramphenicol (33 mg/mL). At the time of induction
the culture was supplemented with 5 mM sodium selenite, 20 mg/
mL riboflavin, 20 mg/mL pyridoxine and 20 mg/mL niacin
according to [21]. The bacterial cultures were centrifuged and
the pellets resuspended in modified Ni-NTA lysis buffer (300 mM
NaCl, 50 mM sodium phosphate, 20 mM imidazole, pH 7.2)
containing 1 mM PMSF and 1 mg/mL lysozyme, and sonicated
(10 pulses of 1 min with 1 min pauses). The lysates were
centrifuged for 1 h at 30,000 g, and supernatants applied to a
Ni-NTA column (Qiagen), washed with 300 mM NaCl, 50 mM
sodium phosphate, 30 mM imidazole, pH 7.2, and eluted with
250 mM imidazole. The protein-containing fractions were applied
to PD10 desalting columns (GE Healthcare) using phosphate-
buffered saline (PBS), 150 mM potassium chloride, 50 mM
sodium phosphate, pH 7.2. Fractions containing the recombinant
protein were stored at 270uC before use. Total protein
concentration and FAD content were determined spectrophoto-
metrically at 280 (e=54.24 mM
21 cm
21) and 460 nm
(e=11.3 mM
21 cm
21), respectively. The selenium content of
Figure 1. Structures of the families of compounds assayed as
inhibitors of flatworm TGR (all compounds assayed are shown
in Table S1). R, R1-R4: variable.
doi:10.1371/journal.pone.0035033.g001
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Plasma Emission Spectrometer (Jarrell-Ash 965 ICP) in Chemical
Analysis Laboratory, University of Georgia. Active selenoenzyme
concentrations were calculated considering their selenium con-
tents. The purity of recombinant proteins was analyzed by running
10% SDS-PAGE gels, under reducing conditions, and by size
exclusion chromatography on a Superose 12 column (GE
Healthcare). Fractions containing recombinant proteins were
stored at 270uC prior to use.
DTNB reduction assay for TR activity
The reduction of 5,59-dithiobis(2-dinitrobenzoic acid) (DTNB)
with concomitant NADPH oxidation was determined by the
increase in absorbance at 412 nm due to the formation of 59-
thionitrobenzoic acid (TNB) (e=13600 M
21 cm
21) [23]. The
reaction mixtures contained 100 mM NADPH and 5 mM DTNB.
GSSG reduction assay
The GR activity was assayed as the NADPH-dependent
reduction of oxidized glutathione (GSSG), which is followed by
the decrease in absorbance at 340 nm due to NADPH oxidation
(e=6200 M
21 cm
21) [24]. The reaction mixtures contained
100 mM NADPH and 100 mM GSSG to avoid conditions of
hysteresis [15,25,26,27].
Inhibition studies
Inhibitor stock solutions were prepared at a final concentration
of 10 mM or 100 mM in dimethylsulfoxide (DMSO). The
screening was performed using the DTNB assay for TR activity.
E. granulosus recombinant TGR was used at a 1 nM final
concentration in all assays. For the initial screening compounds
were assayed at a 10 mM final concentration, except for a few
cases in which compounds were tested at 1 mM, due to non-
constant baselines at 10 mM in control experiments without
enzyme. In all cases TGR was preincubated during 3 minutes with
NADPH and compounds to test, and the reaction started by
addition of DTNB and followed for 3 minutes. All assays were
performed in duplicate. In every case, a control progress curve
without enzyme was performed to control for non-catalyzed
reactions between substrates and inhibitors. The percentage of TR
inhibition was calculated as follows: % Inhibition=1002(vi/
vo)6100, where vi and vo correspond to the initial velocities of
TNB formation (mM)/t (s) with and without inhibitor, respectively.
Compounds inhibiting more than 30% the TR activity under the
conditions assayed were used in further experiments. All active
compounds were assayed for inhibition of GR activity using
recombinant E. granulosus TGR and also screened for TR and GR
inhibition of F. hepatica TGR. Additional characterization was
performed for compounds that showed more than 50% inhibition
under the conditions assayed. We evaluated whether inhibitors
were slow-binding using preincubation times ranging from 3 to
120 minutes. In addition, in order to study the binding of
inhibitors NADPH-enzyme-inhibitors mixes were preincubated as
described above during 30 minutes and then the mixes were
applied to a PD10 column, in order to remove the excess of
unbound inhibitor. The TR activity of the eluates was evaluated
by adding NADPH and DTNB. Control experiments without
inhibitors were carried out in parallel.
In vitro culture of larval worms
50,000 protoscoleces, obtained from asceptical punction of a
single hydatid cyst from bovine lung, were washed several times
with PBS and then incubated at 37uC, 5% CO2, in DMEM
supplemented with antibiotics and 20 mM HEPES, pH 6.8. In all
cases 1,000 protoscoleces were treated with 100, 50 or 20 mM
inhibitor concentrations. Protoscoleces were observed under the
microscope every 4 h and endpoint viability assessed by exclusion
of the vital dye eosin [28] at 48 h. The infected bovine viscera was
obtained as part of the normal discard processing of the abattoir.
In vitro culture of newly excysted juvenile
Metacercariae of F. hepatica were purchased from Baldwin
Aquatics Inc. (Monmouth, Oregon). The in vitro excystment was
performed as previously described in [29], with minor modifica-
tions. Briefly, metacercariae were placed in a 100 mm filter and
incubated 3 min at room temperature with 1% sodium hypochlo-
rite to remove contaminants. After an exhaustive wash in double
distilled H2O, the metacercariae were incubated at 39uCi n
activation media (25 mM HCl and 16,5 mM L-cysteine, 0.1%
sodium taurocholate, 60 mM NaHCO3, 70 mM NaCl pH 8.0),
and the excystment process was monitored under the microscope.
After 90–180 min of incubation, newly excysted juveniles (NEJ)
began to emerge, and were collected, washed several times with
RPMI-1640, pH 7.2, and transferred into 6 wells plates and kept
in culture at 37uC under 5% CO2 with RPMI-1640 media
containing 200 U/mL Penicillin G sulfate, 500 ng/mL ampho-
tericin B, 10 mM HEPES. In all cases 250 NEJ were treated with
20 mM concentration of inhibitors. NEJ were observed under the
microscope every 4 h and endpoint viability assessed by exclusion
of the vital dye eosin at 48 h.
Structure-activity studies
Three types of descriptors were analyzed in this study:
constitutional descriptors, molecular properties and topological
charge indices. The program E-DRAGON (www.vcclab.org/lab/
edragon/) was used to generate the descriptors using the SMILES
code of each molecule. The initial number of descriptors was
submitted to the following reduction procedure: i) descriptors with
constant values for 80% or more of the molecules were excluded;
ii) pairwise correlation was done, and a descriptor was eliminated
if the correlation coefficient with another descriptor was equal to
or higher than 0.9; and iii) only descriptors able to discriminate
between activity classes were selected (t test, t-value.2). For this
purpose, compounds were classified as actives (TGR inhibition
.50%) and inactives (TGR inhibition ,50%). All the reduced
descriptors were autoscaled using the mean and standard
deviation. The ability of the descriptors to discriminate between
activity classes was analyzed using principal components analysis
[30]. The best combination of descriptors was used to classify
compounds using hierarchical cluster analysis (HCA).
Molecular modeling
Molecular modeling of compounds was carried out using the
Spartan’04 program package [31]. Molecular mechanics (MMFF)
was used for preliminary structure optimization and conforma-
tional search as implemented in the program. The minimum
energy conformer was further optimized using density functional
theory (B3LYP/6-31G*). At this level the following properties
were calculated: highest occupied molecular orbital (HOMO)
energy (EHOMO), lowest unoccupied molecular orbital (LUMO)
energy (ELUMO), HOMO-LUMO energy gap (GAP), octanol/
water partition coefficient using Ghose-Crippen method (LogP)
[32], solvation energy using Truhlar model SM5.4 (Esolv) [33],
and module of dipolar moment (m).
Drug Hits for the Control of Flatworm Parasites
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35033Compounds toxicity assays
Murine fibroblasts (L929 cell line) were incubated at 37u with
compounds 1, 2, 3, 5, 22 and 61 (range of concentrations 5–
160 mM) in DMEM supplemented with glutamine and 5% heat-
inactivated fetal bovine serum. Viability was examined 48 hours
later using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) reduction assay [34]. Citotoxicity profiles for
the other active compounds were previously published (see
Toxicity Profile in Text S1, and references therein). Additional
toxicity assays were performed for those compounds that showed
more than 50% inhibition under the initial screening conditions
and effectively killed E. granulosus and F. hepatica at a 20 mM
concentration (compounds 1, 2, 3 and 50). These assays were
carried out using human primary cell cultures and monitoring
toxicity for a longer time (96 hours). Peripheral blood mononu-
clear cells (PBMC, mostly consisting of lymphocytes) were isolated
from whole human blood by centrifugation through Ficoll-
Hypaque solution (HistopaqueH 1077, SIGMA-ALDRICH),
according to Procedure Nu 1077 from the manufacturers. Cells
were incubated in RPMI 1640 supplemented with glutamine, 10%
heat-inactivated fetal bovine serum and antibiotics at concentra-
tions of 10, 20, 40 and 80 mM of each compound. Assays were
carried out in 96 well culture plates containing 150.000 cells per
well. Viability was examined after 96 hours of culture as described
above and by exclusion of the vital dye trypan blue. A written
consent was obtained from the donor according to regulation Nu
282 of the Ethic Committee of the Faculty of Chemistry
(Universidad de la Repu ´blica) and the National Decree Nu 379/
008.
Results
The identified TGR inhibitors belong to different families
of compounds
The sixty five compounds selected as putative TGR inhibitors
are shown in Table S1. These compounds belong to 6 different
families, which are depicted in Figure 1. In total, we examined 21
oxadiazole N-oxides (also known as furoxans), 26 benzofuroxans
(these compounds represent a particular type of oxadiazole N-
oxides), 11 thiadiazoles, 3 quinoxalines, 1 oxathiazole and 1
nitrooxy-derivative. The furoxan family included the compound 4
(4-phenyl-1,2,5-oxadiazole-3-carbonitrile-2-oxide, see Table S1),
a well-known S. mansoni TGR inhibitor with capability to release
nitric oxide (NO) [12,35]. An initial screening for inhibitors was
carried out using the TR assay with DTNB as a substrate. The
rationale to screen the compounds using the TR assay was that
both thioredoxin and glutathione reductase activities are depen-
dent on the TR module of TGR, and therefore its inhibition leads
to ablation of all thiol-disulfide oxidoreductase activities of TGR.
Initially, the compounds were tested at 10 mM concentration; in a
few instances inhibitors were tested at 1 mM (see Material and
Methods). Several oxadiazole N-oxides, benzofuroxans, one
quinoxaline and one thiadiazole significantly inhibited TR activity.
The results are shown in Figures 2 and 3. For further work, we
selected those compounds that inhibited TR activity more than
30% when assayed at either 1 or 10 mM concentration. Under
these criteria, 14 of the 65 tested compounds were shown to inhibit
the TR activity of TGR.
A major finding was that drug hits for S. mansoni TGR
(oxadiazole N-oxides and quinoxalines) also affected the activity of
E. granulosus TGR: several furoxans and benzofuroxans and one of
three quinoxalines inhibited this cestode TGR. The other major
finding was that one thiadiazole was a very good inhibitor of E.
granulosus TGR; indeed, TR inhibition by this thiadiazole was
comparable to the inhibition achieved by the most efective
oxadiazole N-oxides. The most active TGR inhibitors (i.e. those
showing more than 50% inhibition in the screening) were assayed
over a wide range of concentrations of active compounds
(Figure 4). It is interesting to note that the reference compound
that inhibited S. mansoni TGR (compound 4) [14] also inhibited E.
granulosus TGR. For the TR inhibitors identified, we then assayed
the inhibition of GR activity of TGR. All of them inhibited GR
activity; this was expected since inhibition of the TR module leads
to inhibition of both TR and GR activities.
The identified tapeworm TGR inhibitors are also active
against fluke TGR
The identified E. granulosus TGR inhibitors were assayed for
inhibition of TR and GR activities of F. hepatica TGR. All E.
granulosus TGR inhibitors were also active against recombinant F.
hepatica TGR (see Figure 2). The percentage of inhibition of TR
activities of F. hepatica and E. granulosus TGRs were similar. The
oxadiazoles 3 and 4 showed higher percentage of inhibition of TR
activity of F. hepatica TGR (91% and 78% respectively) than the
corresponding inhibition percentage of E. granulosus TGR (73%
and 44%, respectively) at 10 mM. Most remarkably, the thiadia-
zole identified as the best E. granulosus TGR inhibitor (compound
50) also inhibited F. hepatica TGR; inhibition of TR activity
at10 mM was 80% (92% in the case of E. granulosus TGR).
The identified TGR inhibitors are slow-binding and nearly
irreversible
In order to further characterize the best inhibitors we examined
whether the extent of inhibition was time dependent. This cannot
be achieved by following a single time course experiment since
initial velocity conditions, i.e. constant velocities, are lost early
during the DTNB assay At constant inhibitor concentration,
longer preincubation times led to higher inhibition for the all
compounds, indicating that these molecules are slow-binding
inhibitors. The results for compound 1 are shown in Table 1;
similar results were obtained for compounds 2, 3 and 50. Indeed,
the concentrations needed to achieve 50% inhibition after
120 min preincubation time was 10-fold lower than those needed
after 3 min preincubation (data not shown). These results
suggested that these inhibitors could be irreversible. To study
the reversibility of enzyme-inhibitor binding we preincubated
NADPH-enzyme-inhibitors mixes in reaction buffer during
30 minutes and then applied the mixes to a PD10 column in
order to remove the excess of unbound inhibitor. For the four
compounds inhibition persisted after removal of the excess of
inhibitors. In other words, no TR activity was recovered in the
eluates. Furthermore, no activity was recovered even after
allowing for a 30 minutes equilibration of the eluates (i.e. allowing
for inhibitor-enzyme desorption). These results indicated that the
inhibitors are virtually irreversibly bound to the enzyme (i.e. either
covalently or tightly bound to the enzyme).
Preliminary structure-activity relationships
The indication of a SAR pattern is important to identify hit-to-
lead and lead-to-drug transitions [36]. Herein, three types of
descriptors were used to establish a structure-TGR inhibition
relationship; constitutionals descriptors, molecular properties, and
topological charge indices. Initially, we used principal components
analysis (PCA) to assess descriptors that may explain the TGR
inhibitory activity. For this, compounds were separated in activity
classes using our internal definition of hit compound (TGR
inhibition .50%). A low activity class was considered including
Drug Hits for the Control of Flatworm Parasites
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analysis, the following descriptors were found related to TGR
inhibition: molecular volume, number of rings and of six-
membered rings, charge distribution, topological polar surface
area, and unsaturation index. Overall, active compounds were
small in the group of tested compounds. All four active compounds
had an aromatic ring attached to heterocycle (1 and 3) or in its
proximity (2 and 50). The presence of the aromatic ring seems to
be essential for TGR activity since methylfuroxans (6, 8–19, and
21, Table S1) were inactive, with the exception of compound 6
that was moderately active.
Using the descriptors selected by PCA, we then applied
hierarchical cluster analysis (HCA) to obtain an unbiased analysis
of molecular properties related to enzyme inhibition. Here,
compounds were clustered according to structure similarity
without any previous activity tag. HCA identified three clusters.
The first cluster included only inactive compounds, methylfurox-
ans and phenoxybenzofuroxans. These compounds displayed low
electrophilicity among their family classes, which could explain
their lack of activity. The second cluster included the active
furoxan 2 and the active thiadiazole 50, along with benzofuroxans
23 and 24 that had low activity. All these compounds had an
arylsulfonyl (or arylsulfinyl) moiety that could act as an electron-
withdrawing group increasing the heterocycle reactivity or could
be itself a pharmacophore. It is worth noting that the spatial
distribution of the phenylsulfonyl (or phenylsulfinyl) moiety is
relevant for activity. For instance, compounds 23 and 24, both cis
isomers, displayed low activity at 1 mM and the corresponding
Figure 2. Compounds that inhibit TR activity of flatworm TGRs. The % of inhibition of E. granulosus and Fasciola hepatica TGR and molecular
structures are shown for each of the compounds tested. The screening was performed at 10 mM inhibitor concentration, except in those cases
marked with an asterisk, which were assayed at 1 mM (at 10 mM control experiments for these compounds without enzyme showed non-constant
base lines). ND: not determined since no larvicidal effect was observed at the highest concentration for E. granulosus.
doi:10.1371/journal.pone.0035033.g002
Figure 3. Screening of TGR inhibitors. The % of inhibition of TR activity of E. granulosus TGR for each compound is shown (compound structures
can be found in Table S1). The screening was carried out with 10 mM inhibitors, except for those marked with an asterisk, which were assayed at
1 mM (these compounds showed non-constant baselines at 10 mM in control experiments without enzyme). A 1 nM TGR was used in all cases. a.
Oxadiazole N-oxides, b. Benzofuroxans, c. Thiadiazoles, d. Various compound families: quinoxalines (61, 62 and 65), nitrooxy (64) and oxathiazole
(63).
doi:10.1371/journal.pone.0035033.g003
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spatial requirement was observed for compound 43, the only
ethenylbenzofuroxan that displayed low activity at 1 mM, the
corresponding trans isomer is inactive. This effect could hardly be
ascribed to differences in electrophilicity. In fact molecular
modeling showed no differences in electronic properties for
derivatives 24 and 40, suggesting that these substituents could
be participating in an interaction with TGR. Finally, the third
cluster included active compounds 1 and 3 along with low activity
compounds 4 (furoxan derivative), 22 and 25 (benzofuroxan
derivatives), and quinoxaline 61. The majority of these com-
pounds have the presence of an electrophilic moiety such as
chloromethyl, nitroimine, or nitro in common.
Remarkably, the active furoxan derivative 2 was clearly
separated from other furoxan derivatives, and was clustered with
the active thiadiazole 50. Both compounds had a phenylsulfonyl
substituent (p-methylphenylsulfonyl in 50) attached to the
heterocycle. Altogether, this finding suggested that the phenylsul-
fonyl moiety is a new pharmacophore, while the heterocycle ring
was acting as a scaffold. While this hypothesis requires additional
studies, it also supports high structural diversity and flexibility in
the design of TGR inhibitors. On the other hand, the fact that
active compounds were separated into two groups, suggests the
occurrence of different mechanisms of enzyme inhibition.
To further study molecular properties related to TGR inhibition
we used molecular modeling to determine the electronic structure
Figure 4. Inhibition of TR activity of TGR by active compounds. Remaining TR activity as a function of inhibitor concentration is plotted for a.
1, b. 2, c. 3 and d. 50. 1 nM TGR was used in all assays.
doi:10.1371/journal.pone.0035033.g004
Table 1. Effect of preincubation time on TR activity inhibition
of TGR.
Preincubation time (min) Inhibition % (*)
3 48
30 82
60 92
90 96
120 100
(*)1.5 mM of compound 1 was incubated with 1 nM enzyme in the presence of
NADPH and the reaction started by the addition of DTNB. Control experiments
without inhibitors were carried out in parallel to determine the corresponding
vo (initial velocities without inhibitors).
doi:10.1371/journal.pone.0035033.t001
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results obtained supported the PCA/HCA analysis. The energies
of frontier orbitals (highest occupied molecular orbital or HOMO
and lowest unoccupied molecular orbital or LUMO) were similar
for active and inactive compounds in both families. The energy of
the frontier orbitals is related to the compound’s reactivity,
implying that active and inactive compounds have similar
reactivity, and differences in TGR inhibition are probably related
to other factors. While HOMO and LUMO energies are global
properties, related with the reactivity of the whole molecule, their
values contain no information on which atom of the molecule
reacts. To assess local reactivity we used molecular orbital maps
(Figure 5). For furoxans, the LUMO maps showed that the
nitrogen of the N-oxide moiety is the main contributor in active
derivatives 2 and 3 (Figure 5A). In contrast, for inactive
derivatives 9 and 16 the main contributor is nitrogen 3 in the
heterocycle. A similar pattern was observed for benzofuroxans
(Figure 5B). Among the other global properties calculated the
only one that was related to TGR inhibition was lipophilicity
(LogP). Active furoxans are more hydrophobic (higher LogP) than
Figure 5. LUMO maps allow identification of electrophilic centers. LUMO mapped onto a bond surface for studied compounds: a. furoxans,
b. benzofuroxans. Blue areas correspond to regions in which the molecule is most susceptible to nucleophilic attack in active compounds the
nitrogen of N-oxide moieties. The arrows show the difference on LUMO contribution of these nitrogens between active and inactive compounds of
the same family.
doi:10.1371/journal.pone.0035033.g005
Table 2. Characteristics of active and inactive compounds.
Family Compound EHOMO
a (eV) ELUMO
b (eV) GAP
c (eV) LogP
d Esol
e (kcal/mol) m
f (D)
Active furoxans 1 26.94 23.21 23.73 3.9 3.11 3.66
2 27.46 22.49 24.97 4.42 212.75 6.77
3 26.88 21.95 24.93 4.54 21.73 4.73
Inactive furoxans 7 27.09 22.11 24.98 3.16 28.26 4.36
9 26.75 22.60 24.15 3.17 25.16 2.92
11 27.04 22.64 24.40 2.39 21.72 1.58
16 26.81 21.73 25.08 3.4 22.44 3.61
Active benzofuroxans 23 26.35 23.03 23.32 5.05 210.71 3.95
24 26.1 22.74 23.36 5.12 210.70 7.64
Inactive benzofuroxans 34 25.95 23.11 22.84 3.76 214.64 7.16
38 26.19 23.09 23.10 5.40 23.67 2.81
39 25.86 22.80 23.06 5.37 29.56 7.01
40 26.07 22.85 23.22 5.00 210.77 3.07
aHighest occupied molecular orbital energy.
bLowest unoccupied molecular orbital energy.
cHOMO-LUMO energy gap.
dOctanol/water partition coefficient using Ghose-Crippen method.
eSolvation energy using Truhlar model SM5.4.
fDipolar moment.
doi:10.1371/journal.pone.0035033.t002
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absence of hydrophilic substituents such as OH, COOH, and
NH2. This suggests interactions with hydrophobic residues in the
enzyme are important for the biological activity.
Identified inhibitors killed E. granulosus larval worms in
vitro
To test whether E. granulosus TGR inhibitors were active against
parasites, we assessed the effect of active compounds against E.
granulosus larval worms (protoscoleces) in vitro. As a control for in
vitro studies, we used an oxadiazole N-oxide, 19, and a
benzofuroxan, 42, which did not display any TGR inhibition.
The results are shown in Table 3 and indicate that there is a very
good correlation between TGR inhibition and in vitro killing of
larval worms. The fact that inhibitors of TGRs killed larval worms,
but the control oxadiazole N-oxide and benzofuroxan did not is a
strong indication that lethality is due to inhibition of TGR. At the
concentration of 100 mM, 11 out of the 14 compounds assayed
killed 100% of larval worms (Table 3), one of them showed a
moderate larvicidal effect (22) and only 2 of the 14 compounds
assayed (44 and 6) did not exhibit any larvicidal activity within
48 h. At 50 mM most inhibitors also killed larval worms, but the
kinetics of killing differed and it was faster for most active
compounds (data not shown). The best TGR inhibitors (the three
oxadiazole N-oxides 1, 2, and 3, and the thiadiazole 50) were the
most active compounds: they killed between 30 and 40% of the
protoscoleces at 20 mM, after 48 h of culture (see Table 3).
Interestingly, compound 4 that was not among the best inhibitors
of TR activity, exhibited a larvicidal effect comparable to the best
inhibitors. Similarly, in S. mansoni this compound was one of the
most active against the parasite but not the best TGR inhibitor
[35]. Most benzofuroxans that were moderately active inhibitors
of TGR were also moderately effective in killing E. granulosus
protoscoleces. Figure 6 shows protoscoleces treated with
inhibitors and control compounds. The effect of compounds
resulted in total disintegration of E. granulosus protoscolex
parenchyma.
Figure 6. Effect of TGR inhibitors on E. granulosus protoscoleces, tested at 20 mM during 48 h. a. 2 (oxadiazole N-oxide), b. 1 (oxadiazole
N-oxide), c. 4 (oxadiazole N-oxide), d. 61 (quinoxaline), e. 50 (thiadiazole), f. control.
doi:10.1371/journal.pone.0035033.g006
Table 3. E. granulosus protoscolex viability in vitro after 48 h incubation with TGR inhibitors at different concentrations.
Compound
Protoscolex viability
(%) at 100 mM
Protoscolex viability
(%) at 50 mM
Protoscolex viability
(%) at 20 mM % TR inhibition at 10 mM
2 0 0 60 85
1 0 0 63 92
3 0 0 70 73
4 0 0 70 44
5 00 1 0 0 3 7
6 100 ND ND 38
43 0 0 90 35
(*)
25 0 0 90 30
23 0 0 90 38
24 00 1 0 0 3 6
22 30 65 100 38
44 100 ND ND 35
(*)
50 0 0 65 92
61 0 0 90 44
19 100 (control) ND ND 6
42 100 (control) ND ND 0
ND: not determined (since no effect was observed at the highest concentration). 42 (benzofuroxan control) and 19 (oxadiazole N-oxide control). A control with vehicle
alone (DMSO) was also included and did not affect protoscolex viability.
(*)% of inhibition of TR activity at 1 mM not at 10 mM.
doi:10.1371/journal.pone.0035033.t003
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juvenile larval worms in vitro
We tested the TGR inhibitors that killed the E. granulosus
protoscoleces in vitro on the trematode parasite F. hepatica. The 12
active compounds (and the two controls, 19, and 42) were tested in
vitro on newly excysted juveniles (NEJ) at 20 mM; the results are
shown in Table 4. Similarly to the results obtained with E.
granulosus protoscoleces, the control compounds had no effect, and
most of the compounds tested (except a furoxan and a couple of
benzofuroxans, 5, 22, and 43) killed more than 80% NEJ. Overall,
F. hepatica NEJ were more sensitive than E. granulosus protoscoleces
to TGR inhibitors when examined at 20 mM. Similar to what was
observed with E. granulosus protoscoleces, compound 4 killed NEJ
with similar efficacy to most active TGR inhibitors. Remarkably,
the thiadiazole identified as TGR inhibitor, 50, was also effective
in vitro against a trematode parasite. Of the five benzofuroxans
assayed, three (23, 24 and 25) were very effective in killing NEJ;
two of the active ones contained the phenylsulfonyl (phenylsulfinyl)
moiety, also present in some active furoxans and the identified
thiadiazole. Figure 7 shows NEJ treated with inhibitors and
control compounds. Lack of parasite material precluded testing the
most active compounds at lower concentrations during longer
periods of exposure to the compounds.
Identified inhibitors are not toxic to human lymphocytes
at the larvicidal concentrations
To examine if most active compounds are toxic to human
primary cells we performed in vitro culture of PBMC with these
compounds at concentrations ranging from 10 to 80 mM and
tested cell viability after 96 hours of culture. Only marginal
toxicity was observed at 20 mM (above 92% viability). Compounds
were still tolerated at 80 mM concentrations and viability ranged
from 49 to 80% at this concentration after 96 hours of incubation.
Additional citotoxicity data using mammalian cell lines are
provided for all active compounds in Text S1.
Discussion
Flatworm infections are chronic and debilitating diseases and
there is a very restricted set of drugs and a few rational drug
targets. The identification of novel drugs, in particular if they
target the parasite by a different mechanism, remains as an
important challenge in medicinal chemistry. TGR is a promising
target for drug screening for flatworm infections. Two features
make this enzyme particularly attractive: it is a drugabble enzyme
and its inhibition leads to disruption in redox homeostasis of
flatworm parasites. Based on these premises we selected, from
previously synthesized products in our chemical library, a range of
candidate TGR inhibitors, based on literature mining and the
reactive nature (nucleophilicity) of the selenocysteine residue of
TGR. The selection included compounds belonging to different
structural families: oxadiazole N-oxide or furoxan (21), benzofur-
oxan (28), thiadiazole (11), quinoxaline (3), nitrooxy-derivative (1)
and oxathiazole (1) (see Table S1 and references therein).
A first interesting observation was that a good selection of
compounds was accomplished: 14 out of 65 selected compounds
inhibited both TR and GR activities of TGR. We identified
Figure 7. Effect of TGR inhibitors on F. hepatica newly excysted juvenile, tested at 20 mM during 48 h. a. 2 (oxadiazole N-oxide), b. 1
(oxadiazole N-oxide), c. 4 (oxadiazole N-oxide), d. 61 (quinoxaline), e. 50 (thiadiazole), f. control.
doi:10.1371/journal.pone.0035033.g007
Table 4. F. hepatica newly excysted juveniles viability in vitro
after 48 h incubation with TGR inhibitors at 20 mM.
Compound NEJ viability (%) at 20 mM
2 0
3 0
4 0
1 14
5 80
25 10
23 16
24 19
22 66
43 85
50 18
61 12
19 100 (control)
42 100 (control)
A control with vehicle alone (DMSO) was also included and did not affect NEJ
viability.
doi:10.1371/journal.pone.0035033.t004
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inhibitors. These families of compounds have previously been
identified as inhibitors of S. mansoni TGR and as drug hits for
schistosomiasis. Therefore our results validate and expand
previous results [12,13,14]: we showed that these compounds
inhibited another fluke TGR (F. hepatica), and, more importantly,
they also inhibited a tapeworm TGR (E. granulosus). Thus, these
two families of compounds can be considered as drug hits for
flatworm parasites, and not only for flukes. Another important
result of our study is the identification of a thiadiazole (50)a sa
potent inhibitor of both fluke and tapeworm TGRs, indicating that
this family of compounds deserves further studies. It is noteworthy
that only 1 out of 11 thiadiazoles inhibited TGR, and therefore the
possibility of thiadiazole as a true drug hit remains to be further
explored. A striking finding of our studies is that the phenylsulfo-
nyl/phenylsulfinyl) moiety correlated very well with TGR
inhibition. Furthermore, active compounds belonging to different
families -oxadiazole N-oxides 2 and 5, benzofuroxans 23 and 24
(the related sulfinyl-moiety in the latter case) and thiadiazole 50-
possessed this group, suggesting that it may be a new pharmaco-
phore. Remarkably, two of them were among the best three TGR
inhibitors and parasite killers found in our study. In this sense, and
taking into account the chemical structures of previously described
TGR-inhibitors (i.e. compounds (I)–(III), Figure 8 ([13,14]) one
could speculate that the scaffold aryl-X=O, where X is P, S, or C,
plays a relevant role in the enzymatic inhibition.
Since a relatively large number of oxadiazoles were examined in
this screening, our results also shed light on the substituents on the
heterocycle ring that may enhance or disfavor inhibition: C3 and
C4 positions of the heterocycle are key to optimize inhibitor
activity. Indeed, we found that a methyl substituent in C3 of the
ozadiazole ring and very large substituents as well as aliphatic/
hydrophilic substituent in C4 appeared to be detrimental to
inhibition. Similar observations were made by Rai et al. [12]. In
contrast, the presence of an electrophilic/electron-withdrawing
group as a substituent in C3 favored inhibition. Similarly, a phenyl
substituent in C4 favors inhibition, probably as an additional
electron-withdrawing group that increases the reactivity of the
furoxan system. The benzofuroxans represented the other large
family examined (28 compounds). Although none of these
compounds was as active as oxadiazoles, active benzofuroxans
were, as in the case of furoxans, those with the presence of an
electrophilic/electron-withdrawing group as benzo-substituent.
The existence of a SAR pattern supported the idea that the hits
were not random, and that they represent promising hit/lead
structures for the development of anti-parasitic drugs. The high
attrition rates observed in HTS of antiparasitic compounds is
sometimes related to the lack of correlation between enzyme
inhibition and cell activity. One main reason for this is dubious
validation status of the target enzyme. Herein, we showed that hit
compounds found in an in vitro TGR assay displayed a good
correlation with antiparasitic activity, supporting TGR as a valid
target in the development of drugs against tapeworm and fluke
parasites.
For all inhibitors the percentage of inhibition found for F.
hepatica and E. granulosus TGRs correlated well between both, fluke
and tapeworm, enzymes. More importantly, in both cases TGR
inhibition correlated very well with the in vitro assays using E.
granulosus protoscoleces and F. hepatica NEJ: 10 of the identified
inhibitors effectively killed parasites in vitro. Noteworthy is the fact
that the most effective TGR inhibitors were those that killed
parasites at lower doses. The consistency of the results strongly
indicates that, in all likelihood, the antiparasitic effect observed for
the compounds is due to inhibition of this essential enzyme. An
exception to this trend is compound 4, which is not within the
most potent inhibitors of E. granulosus TGR, but very effective in
killing larval worms. Indeed, this compound has been found to be
a more potent oxadiazole N-oxide, due to increased nitric oxide
release [12], suggesting that this mechanism contributes to its
toxicity. It is interesting to highlight that compounds 1, 2 and 3
showed an excellent correlation between enzyme inhibition and
parasite killing. In this context, it is relevant to emphasize that
these three compounds were found to slowly and irreversibly bind
TGR. Thus, our results suggest that nitric oxide release and
nitrosylation may play a role in their efficacy as TGR inhibitors
and parasite killers. Finally, it should be mentioned that other
mechanism(s) different form NO release could lead to slow and
nearly irreversible inhibition of TGR as illustrated by the strong
inhibition displayed by the identified thiadiazole substituted with
the phenylsulfonyl moeity.
Our results reinforce the concept that the redox metabolism of
flatworm parasites is particularly susceptible to destabilization, and
that the TR module of TGR is a ‘‘druggable’’ target that leads to
redox unbalance in flatworms. Specifically we showed that
furoxans and quinoxalines are drug hits not only for flukes but
also for tapeworms, and identified new drug hits for both classes of
flatworm parasites. Since the biochemical scenario of flatworm
parasites is very similar regarding the thiol redox-dependent
pathways [9,10,11,26], our results highlight that TGR inhibitors
have broad applications for the control of a wide range of
neglected diseases.
Supporting Information
Text S1 Information about toxicity of inhibitors of
TGR. Toxicity profiles have previously been analyzed in vitro on
mammalian cells for the compounds analyzed in vitro against E.
granulosus protoscolex and F. hepatica newly excysted juveniles. For
some compounds mutagenicity studies by Ames’ test and
genotoxicity studies by comet assay were carried out.
(DOC)
Table S1 Inhibition % of TR activity for all compounds
used in the screening of TGR inhibitors.
(DOC)
Figure 8. Structures of the most potent compounds described
herein (2, 23, and 50) and several previously described TGR
inhibitors ((I), (II), and (III)) ([13,14]). Structural motives are marked.
doi:10.1371/journal.pone.0035033.g008
Drug Hits for the Control of Flatworm Parasites
PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e35033Acknowledgments
We greatly appreciate the gift of pSUABC from Dr. Elias Arne ´r
(Karolinska Institutet) and the technical advice of Dr. Ana Ferreira and
Lucı ´a Minarrieta on toxicity assays on mammalian cells. We would like
thank the personnel of UREXPORT for provision of hydatid material
from bovine infected viscera.
Author Contributions
Conceived and designed the experiments: HC MG M. Boiani MF GS.
Analyzed the data: FR HC MG VNG M. Boiani M. Bonilla MF GS.
Contributed reagents/materials/analysis tools: TB GM M. Bonilla PH WP
GVL M. Boiani MF HC MG. Wrote the paper: GS VNG HC MG MB M.
Boiani CC. Performed the enzymatic inhibition studies: FR GS. Performed
the in vitro studies with larval worms and NEJ: GS. Performed the in vitro
excystment of metacercariae: TB. Cloned and prepared recombinant F.
hepatica TGR: GM. Cloned and prepared recombinant E. granulosus TGR:
M. Bonilla. Performed the syntheses of the studied compounds: PH WP
GVL M. Boiani HC MG.
References
1. Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, et al. (2008) Helminth
infections: the great neglected tropical diseases. J Clin Invest 118: 1311–1321.
2. WHO website. Available: http://www.who.int/whr/2004/en/report04_en.pdf.
Accesed 2012 Mar 14.
3. Keiser J, Utzinger J (2005) Emerging foodborne trematodiasis. Emerg Infect Dis
11: 1507–1514.
4. Brennan GP, Fairweather I, Trudgett A, Hoey E, McCoy, et al. (2007)
Understanding triclabendazole resistance. Exp Mol Pathol 82: 104–109.
5. Torgerson PR, Budke CM (2003) Echinococcosis–an international public health
challenge. Res Vet Sci 74: 191–202.
6. Kern P (2010) Clinical features and treatment of alveolar echinococcosis. Curr
Opin Infect Dis 23: 505–512.
7. Cioli D, Valle C, Angelucci F, Miele AE (2008) Will new antischistosomal drugs
finally emerge? Trends Parasitol 24: 379–382.
8. Mansour T (2002) Antimalarial Agents and their targets. In: Mansour T, ed.
Chemotherapeutic Targets in Parasites Contemporary strategies. Cambridge:
Cambridge University Press.
9. Alger HM, Williams DL (2002) The disulfide redox system of Schistosoma
mansoni and the importance of a multifunctional enzyme, thioredoxin
glutathione reductase. Mol Biochem Parasitol 121: 129–139.
10. Otero L, Bonilla M, Protasio AV, Fernandez C, Gladyshev VN, et al. (2010)
Thioredoxin and glutathione systems differ in parasitic and free-living
platyhelminths. BMC Genomics 11: 237.
11. Salinas G, Selkirk ME, Chalar C, Maizels RM, Ferna ´ndez C (2004) Linked
thioredoxin-glutathione systems in platyhelminths. Trends in Parasitology 20:
340–346.
12. Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, et al. (2009) Structure
mechanism insights and the role of nitric oxide donation guide the development
of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. J Med
Chem 52: 6474–6483.
13. Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, et al. (2008)
Identification of oxadiazoles as new drug leads for the control of schistosomiasis.
Nat Med 14: 407–412.
14. Simeonov A, Jadhav A, Sayed AA, Wang Y, Nelson ME, et al. (2008)
Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma
mansoni Redox Cascade. PLoS Negl Trop Dis 2: e127.
15. Bonilla M, Denicola A, Novoselov SV, Turanov AA, Protasio A, et al. (2008)
Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a
single thioredoxin glutathione reductase and dependent on selenium and
glutathione. J Biol Chem 283: 17898–17907.
16. Martinez-Gonzalez JJ, Guevara-Flores A, Alvarez G, Rendon-Gomez JL, Del
Arenal IP (2010) In vitro killing action of auranofin on Taenia crassiceps
metacestode (cysticerci) and inactivation of thioredoxin-glutathione reductase
(TGR). Parasitol Res 107: 227–231.
17. Andricopulo AD, Akoachere MB, Krogh R, Nickel C, McLeish MJ, et al. (2006)
Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential
antimalarial agents. Bioorg Med Chem Lett 16: 2283–2292.
18. Maggioli G, Silveira F, Martin-Alonso JM, Salinas G, Carmona C, et al. (2011)
A recombinant thioredoxin-glutathione reductase from Fasciola hepatica
induces a protective response in rabbits. Exp Parasitol 129: 323–330.
19. Arner ESJ, Sarioglu H, Lottspeich F, Holmgren A, Bock A (1999) High-level
expression in Escherichia coli of selenocysteine-containing rat thioredoxin
reductase utilizing gene fusions with engineered bacterial-type SECIS elements
and co-expression with the selA, selB and selC genes. Journal of Molecular
Biology 292: 1003–1016.
20. Rengby O, Johansson L, Carlson LA, Serini E, Vlamis-Gardikas A, et al. (2004)
Assessment of Production Conditions for Efficient Use of Escherichia coli in
High-Yield Heterologous Recombinant Selenoprotein Synthesis. Appl Environ
Microbiol 70: 5159–5167.
21. Bar-Noy S, Gorlatov SN, Stadtman TC (2001) Overexpression of wild type and
SecCys/Cys mutant of human thioredoxin reductase in E. coli: the role of
selenocysteine in the catalytic activity. Free Rad Biol Med 30: 51–61.
22. Mu ¨ller S, Heider J, Bo ¨ck A (1997) The path of unspecific incorporation of
selenium in Escherichia coli. Arch Microbiol 168: 421–427.
23. Arner ESJ, Zhong L, Holmgren A (1999) Preparation and assay of mammalian
thioredoxin and thioredoxin reductase Methods Enzymol: Academic Press. pp
226–239.
24. Carlberg I, Mannervik B (1985) Glutathione reductase. Methods Enzymol 113:
484–490.
25. Guevara-Flores A, Pardo JP, Rendon JL (2011) Hysteresis in thioredoxin-
glutathione reductase (TGR) from the adult stage of the liver fluke Fasciola
hepatica. Parasitol Int 60: 156–160.
26. Huang HH, Day L, Cass CL, Ballou DP, Williams CH, et al. (2011)
Investigations of the Catalytic Mechanism of Thioredoxin Glutathione
Reductase from Schistosoma mansoni. Biochemistry.
27. Rendo ´n JL, del Arenal IP, Guevara-Flores A, Uribe A, Plancarte A, et al. (2004)
Purification, characterization and kinetic properties of the multifunctional
thioredoxin-glutathione reductase form Taenia crassiceps metacestode (cysticerci).
Molecular and Biochemical Parasitology. pp 61–69.
28. Baz A, Hernandez A, Dematteis S, Carol H, Nieto A (1995) Idiotypic
modulation of the antibody response of mice to Echinococcus granulosus
antigens. Immunology 84: 350–354.
29. Carmona C, Dowd AJ, Smith AM, Dalton JP (1993) Cathepsin L proteinase
secreted by Fasciola hepatica in vitro prevents antibody-mediated eosinophil
attachment to newly excysted juveniles. Mol Biochem Parasitol 62: 9–17.
30. Jolliffe IT (2002) Principal Component Analysis. New York: Springer-Verlag
Inc.
31. Wavefunction website. Available: http://www.wavefun.com/japan/spartan
04win_online_j/Main.html. Accesed 2012 Mar 14.
32. Ghose AK, Crippen GM (1987) Atomic physicochemical parameters for three-
dimensional-structure-directed quantitative structure-activity relationships. 2.
Modeling dispersive and hydrophobic interactions. J Chem Inf Comput Sci 27:
21–35.
33. Storer JW, Giesen DJ, Hawkins GD, Lynch GC, Cramer CJ, et al. (1994)
Solvation Modeling in Aqueous and Nonaqueous Solvents: New Techniques
and a Re-examination of the Claisen Rearrangement. In: Cramer CJ,
Truhlar DG, eds. Structure and Reactivity in Aqueous Solution. Washington,
DC: American Chemical Society.
34. Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K (1986) An
improved colorimetric assay for interleukin 2. J Immunol Methods 93: 157–165.
35. Rai G, Thomas CJ, Leister W, Maloney DJ (2009) Synthesis of Oxadiazole-2-
oxide Analogues as Potential Antischistosomal Agents. Tetrahedron Lett 50:
1710–1713.
36. Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, et al. (2009) Advancing drug
innovation for neglected diseases-criteria for lead progression. PLoS Negl Trop
Dis 3: e440.
Drug Hits for the Control of Flatworm Parasites
PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e35033